Global Monocyte Activation Test Market Size Study, by Product (MAT Kits, Reagents), by Source (PBMC Based, Cell Line Based), by Application (Drug Development, Vaccine Development, Medical Device Testing, Others), by End Use (Pharmaceutical Industry, Biote

The Global Monocyte Activation Test (MAT) Market was valued at approximately USD 511.99 million in 2023 and is anticipated to grow at a CAGR of 15.9% over the forecast period 2024-2032. The rising demand for safer pharmaceutical and biopharmaceutical products, coupled with the increased adoption of in-vitro alternatives to animal testing, is driving market growth. Regulatory agencies, including the FDA and European Pharmacopeia, have actively endorsed MAT, accelerating its market adoption. Additionally, the increasing awareness of ethical testing methods, along with ongoing advancements in MAT technology, is fostering industry expansion. The growing prevalence of chronic diseases and the rise in biologics development necessitate accurate pyrogen detection, further boosting market demand. Technological innovations, including luciferase-based assays and cryopreserved PBMC-based testing, are improving the reliability and efficiency of MAT, solidifying its presence in the industry.

The regulatory landscape is significantly influencing the MAT market, especially in Europe, where the European Pharmacopoeia Commission (EPC) has mandated the elimination of the Rabbit Pyrogen Test (RPT) by July 2025, transitioning to in-vitro testing methods such as MAT. This shift aligns with global sustainability goals and ensures the safety, efficacy, and quality of drugs, vaccines, and medical devices. Pharmaceutical and biotechnology companies are integrating MAT into quality control procedures as it provides more accurate human inflammatory response assessments compared to conventional methods. These factors have accelerated the adoption of MAT, reinforcing its position as the gold standard in pyrogen testing.

The MAT market is experiencing a technological evolution with the introduction of next-generation testing solutions. Innovations like Lonza Bioscience’s PyroCell MAT System, which employs cryopreserved PBMCs, are eliminating donor qualification challenges and enhancing assay efficiency. These advancements address lot-to-lot variability and reduce labor-intensive processes, ensuring on-demand testing for pharmaceuticals and biologics. Moreover, novel LumiMAT™ assays, leveraging luciferase-based reporter genes, have revolutionized high-sensitivity pyrogen detection, eliminating reliance on ELISA-based techniques. This transition towards automation and standardization is ensuring greater accuracy and repeatability in MAT applications across the pharmaceutical and biotechnology industries.

From a geographical perspective, North America dominates the market due to its strong pharmaceutical and biotechnology sectors, stringent regulatory guidelines, and widespread adoption of advanced in-vitro testing methodologies. Europe follows closely, propelled by regulatory mandates phasing out animal-based testing methods. Meanwhile, Asia-Pacific is expected to witness the fastest growth, with China, Japan, and India emerging as leading adopters due to the expansion of biopharmaceutical manufacturing and regulatory enhancements. The increasing global shift towards in-vitro, ethical, and sustainable testing methodologies continues to solidify MAT’s position as the preferred solution for pyrogen detection.

Major Market Players Included in This Report Are:
• Lonza Group
• Charles River Laboratories
• Bio-Rad Laboratories
• Merck KGaA
• Seikagaku Corporation
• Hyglos GmbH
• Wako Chemicals USA
• Thermo Fisher Scientific
• MAT BioTech
• Eurofins Scientific
• Sanquin Reagents B.V.
• FUJIFILM Wako Pure Chemical Corporation
• Nelson Laboratories, LLC
• GenScript Biotech Corporation
• Sartorius AG

The Detailed Segments and Sub-Segments of the Market Are Explained Below:

By Product
• MAT Kits
• Reagents

By Source
• PBMC Based
• Cell Line Based

By Application
• Drug Development
• Vaccine Development
• Medical Device Testing
• Others

By End-Use
• Pharmaceutical Industry
• Biotechnology Industry
• Medical Device Industry
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of MEA

Years Considered for the Study Are As Follows:
• Historical Year: 2022
• Base Year: 2023
• Forecast Period: 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 Years (2022-2032)
• Annualized Revenue and Regional Analysis for Each Market Segment
• Geographical Landscape with Country-Level Analysis for Major Regions
• Competitive Landscape with Key Market Players
• Analysis of Key Business Strategies and Recommendations for Market Approach
• Demand-Side and Supply-Side Market Analysis

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more